While targeting LPA1 holds promise, several challenges need to be addressed. The redundancy and overlapping functions of LPA receptors can complicate therapeutic interventions. LPA1 shares ligands and signaling pathways with other LPA receptors, such as LPA2 and LPA3, which might compensate for LPA1 inhibition. Hence, selective inhibition of LPA1 without affecting other receptors is crucial. Additionally, understanding the complex tumor microenvironment and patient-specific factors is necessary for effective treatment strategies.
